FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~October 415, 2025

CRISPR THERAPEUTICS AG

(Exact name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its~~Its ~~charter~~Charter)

Switzerland	001-37923	Not Applicable
(State or other jurisdictionof incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
Baarerstrasse 14
6300 Zug, Switzerland		Not Applicable
(Address of principal executive offices)		(Zip Code)
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s ~~telephone~~Telephone ~~number~~Number, ~~including~~Including ~~area~~Area ~~code~~Code: 41 (0)41 561 32 77

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Shares, nominal value CHF 0.03		CRSP		The ~~NASDAQ~~Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 28.0201 ResultsOther of Operations and Financial ConditionEvents.

OnAs previously reported, on August 430, ~~2025~~2019, CRISPR Therapeutics AG ~~announced~~(the ~~its~~“Company”) ~~financial~~entered ~~results~~into ~~for~~an Open Market Sale AgreementTM (the ~~quarter~~“Agreement”) ~~ended~~with ~~June~~Jefferies 30LLC (“Jefferies”), ~~2025~~under which the Company may offer and ~~other~~sell, ~~business~~from ~~highlights.~~time ~~The~~to ~~full~~time ~~text~~at ofits ~~the~~sole ~~press~~discretion ~~release~~through ~~issued~~Jefferies, inas ~~connection~~its ~~with~~sales ~~the~~agent, ~~announcement~~its iscommon ~~furnished~~shares, asnominal ~~Exhibit~~value ~~99.1~~of toCHF ~~this~~0.03 ~~Current~~per ~~Report~~share on(the ~~Form~~“Common ~~8-K~~Shares”).

~~The~~On ~~information~~October in15, ~~this~~2025, ~~Form~~the ~~8-K~~Company ~~(including~~filed ~~Exhibit~~a 99prospectus supplement with the U.1)S. ~~shall~~Securities ~~not~~and beExchange ~~deemed~~Commission (the “~~filed~~SEC”) ~~for~~to ~~purposes~~offer ofand ~~Section~~sell 18from oftime ~~the~~to ~~Securities~~time ~~Exchange~~at ~~Act~~its ofsole ~~1934~~discretion through Jefferies, as ~~amended~~its ~~(the~~sales ~~“Exchange Act”)~~agent, oradditional ~~otherwise~~Common ~~subject~~Shares tohaving ~~the~~an ~~liabilities~~aggregate offering price of ~~that~~up ~~section~~to $600,000,000 ~~nor~~(the ~~shall~~“Offering”). itThe beCommon ~~deemed~~Shares ~~incorporated~~for bythe ~~reference~~Offering inwill ~~any~~be ~~filing~~offered ~~under~~and sold pursuant to the ~~Securities~~Company’s ~~Act~~previously offiled ~~1933,~~automatically aseffective ~~amended,~~shelf orregistration ~~the~~statement ~~Exchange~~on ~~Act,~~Form ~~except~~S-3ASR as(File ~~expressly~~No. ~~set~~333-281262) ~~forth~~filed by ~~specific~~the ~~reference~~Company inwith ~~such~~the aSEC ~~filing~~on August 5, 2024.

The legal opinion of Walder Wyss AG relating to the legality of the issuance and sale of the Common Shares in the Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:


Exhibit No.		Description

5.1*		Opinion of Walder Wyss AG

23.1*		Consent of Walder Wyss (included in Exhibit 5.1)

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

ExhibitNo.		Description
99.1		Press Release by CRISPR Therapeutics AG, dated August 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~thereunto~~hereunto duly authorized.

			CRISPR Therapeutics AG
Date:	~~August~~October 415, 2025	By:	/s/ Samarth Kulkarni
			Samarth Kulkarni, Ph.D.Chief Executive Officer

Filing Compare · CRISPR Therapeutics AG